Pharmaceutical company Pfizer, in partnership with Geneva-based non-profit organization Medicines Patent Pool and with UN support, intends to offer poorer countries its new coronavirus drug at significantly reduced prices.
The drug, which Pfizer will market under the name Paxlovid, has been shown in clinical trials to be highly effective in preventing severe disease in unvaccinated individuals.
The company will negotiate the mass production of its tablets with a dozen OTC manufacturers, which will be available to 95 countries, mainly in Asia and Africa, with a population of 4 billion people – more than half of the world’s population. The deal will not affect a number of countries, including Brazil, Cuba, Iraq, Libya, China and Russia.
Pfizer will not charge royalties from sales of its drug in the countries covered by the agreement. Pharmaceutical company Merck has entered into a similar licensing agreement for its antiviral drug molnupiravir.
Medicines “on sale”